Jump to content

Doxanthrine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 02:05, 17 January 2014 (Fix CS1 deprecated date parameter errors). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Doxanthrine
Clinical data
ATC code
  • none
Identifiers
  • (6aS,12bR)-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline-2,3-diol
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H15NO3
Molar mass269.295 g/mol g·mol−1
3D model (JSmol)
  • Oc4cc2C3c1ccccc1CNC3COc2cc4O
  (verify)

Doxanthrine is a synthetic compound which is a potent and selective full agonist for the dopamine D1 receptor.[1][2]

References

  1. ^ Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE (November 2006). "trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist". Journal of Medicinal Chemistry. 49 (23): 6848–57. doi:10.1021/jm0604979. PMID 17154515.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ (February 2009). "Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 19 (2): 138–46. doi:10.1016/j.euroneuro.2008.10.002. PMC 2636714. PMID 19028082.{{cite journal}}: CS1 maint: multiple names: authors list (link)